Clinical trials: PFS
Neuroendocrine Tumors
Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients
The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Dotatate in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine…
- Trial name
- NCT03422029
- Testing
- 177Lu-Dotatate PRRT
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University
Colorectal Cancer
Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer
This is an observational, ambispective cohort study. The aim is to compare the efficacy and safety of regorafenib versus fruquintinib conducted in China.
- Trial name
- NCT04431791
- Testing
- Regorafenib, Fruquintinib
- Where
- China
- Volunteers
- 268 people
- Sponsor
- Peking University
PFS
Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous Cell
A prospective, single arm, single center, phase II clinical trial of neoadjuvant chemotherapy with camrelizumab in locally advanced esophageal squamous cell,to evaluate the progression free survival
- Trial name
- NCT04520035
- Testing
- camrelizumab, Paclitaxel, Neoadjuvant Chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy
Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
This study aims to investigate the efficacy and safety of neoadjuvant cadonilimab in combination with perioperative SOX chemotherapy, compared to perioperative SOX chemotherapy alone, in patients with diffuse or mixed-type…
- Conditions
- Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate
- Trial name
- NCT06949033
- Testing
- Neoadjuvant cadonilimab combined with perioperative SOX
- Where
- 4 sites in China
- Volunteers
- 668 people
- Sponsor
- Zuoyi Jiao
Neuroendocrine Tumors
PFS and OS of Patients With Advanced Neuroendocrine Cancer (NEN) After Systemic Treatment
This is a retrospective study. The analysis includes patients with advanced neuroendocrine cancer (NEN) treated with systemic therapy, because of inoperable primary tumor or/and metastasis, clinical, imaging, biochemical disease…
- Trial name
- NCT04331912
- Where
- 2 sites in Poland
- Volunteers
- 100 people
- Sponsor
- University of Warmia and Mazury
Non Small Cell Lung Cancer
ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in NSCLC
Assess the PFS/ORR/OS of ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in first Treatment of NSCLC
- Trial name
- NCT01810367
- Testing
- ABX Combined With Cisplatin, Gemcitabine Combined With Cisplatin
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Fudan University
Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
The study will compare the safety of ophthalmic bevacizumab in vials versus pre-filled syringes in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab…
- Conditions
- Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion
- Trial name
- NORSE SEVEN (NCT05112861)
- Testing
- bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Outlook Therapeutics, Inc.
Hyperfibrinogenemia, Hemostatic Disorder
Coagulation Disorders Secondary to Two Plasmapheresis Techniques (Double Filtration Plasmapheresis vs. PFS). Descriptive Pilot Study.
Therapeutic plasmapheresis causes changes in haemostasis by purifying many of the circulating factors involved. Few reliable data are available on these changes and most studies are limited to coagulation factor assays before and…
- Trial name
- APHERCOAG (NCT06571552)
- Testing
- Single Plasma Exchange followed by Double Filtration Plasmapheresis
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Disorder Related to Bone Marrow Transplantation, Leukemia
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
The goal of this clinical research study is to learn if combining busulfan with clofarabine and fludarabine can help control the disease better than the previous standard method (using busulfan and fludarabine alone) in patients…
- Conditions
- Disorder Related to Bone Marrow Transplantation, Leukemia, Transplantation Infection
- Trial name
- NCT01471444
- Testing
- Fludarabine, Clofarabine, Busulfan
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- M.D. Anderson Cancer Center
Patients With Alzheimer's Disease
Modelling in the Quantitative Analysis of Brain PET Scans in Patients With Alzheimer's Disease
PET/CT scans with 18F-FDG can be carried out for the detection of neurodegenerative diseases with hypometabolisms characteristic of the pathologies sought.
- Trial name
- PET-SF (NCT04718207)
- Testing
- Brain positron emission tomopgraphy (PET) - scan
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Central Hospital, Nancy, France
Melanoma
Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
The goal of this clinical research study is to learn if the combination of ipilimumab and ABI-007 (abraxane) can help to control metastatic melanoma. The safety of this drug combination will also be studied.
- Trial name
- NCT01827111
- Testing
- ABI-007, Ipilimumab, Phone Call
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Neovascular Age-related Macular Degeneration, Macular Oedema Secondary to RVO
A Trial to Evaluate the Safety and Usability of the SB15 PFS in Trial Participants With AMD, Macular Oedema Secondary to RVO, or Diabetic Macular Oedema
This is an open label, multicenter, Phase II trial to evaluate the safety and usability of the pre-filled syringe (PFS) of SB15 (Aflibercept biosimilar).
- Conditions
- Neovascular Age-related Macular Degeneration, Macular Oedema Secondary to RVO, Diabetic Macular Oedema
- Trial name
- NCT07844343
- Testing
- SB15 PFS
- Where
- 3 sites in South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Lymphoma
A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
There are 2 parts to this study: Part 1 (dose de-escalation) and Part 2 (dose expansion). The goal of Part 1 of this clinical research study is to find the highest tolerable dose of lenalidomide in combination with obinutuzumab…
- Trial name
- NCT02529852
- Testing
- Lenalidomide, Obinutuzumab, Cyclophosphamide
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- M.D. Anderson Cancer Center
Neuroendocrine Tumors
Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer
This is a non-randomized, phase II, open label study. The purpose of this study is to estimate Progression Free Survival (PFS) after treatment with Peptide Receptor Radionuclide Therapy (PRRT) 177Lu-DOTATOC standard dose (up to…
- Trial name
- NCT04194125
- Testing
- 177Lu-DOTATOC
- Where
- Poland
- Volunteers
- 25 people
- Sponsor
- University of Warmia and Mazury
The Primary Study Metric is Progression-free Survival (PFS)
A Retrospective Study of Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant Lung Cancer
Objective: To investigate the efficacy and safety of radiotherapy combined with EGFR-KI in the treatment of stage III EGFR mutant lung cancer.
- Trial name
- NCT05934461
- Volunteers
- 48 people
- Sponsor
- Laibin People's Hospital
Locally Advanced Head and Neck Squamous Cell Carcinoma
Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma
The guidelines for locally advanced head and neck squamous cell carcinoma currently recommend surgery / radiotherapy / chemotherapy / targeted therapy.
- Trial name
- NCT05773079
- Testing
- Toripalimab
- Volunteers
- 28 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Colorectal Cancer
OPTIMOX1 in Chinese mCRC Patients
Previous OPTIMOX1 study investigated the use of oxaliplatin discontinuation and reintroduction in a novel stop-and-go strategy. Previously untreated patients were randomly assigned to either FOLFOX4 administered every 2 weeks…
- Trial name
- NCT01023633
- Testing
- Oxaliplatin, LV, 5-FU
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Nanjing Medical University
Primary Central Nervous System Lymphoma
A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma
To observe the efficacy and safety of a new generation of BTK inhibitor Orelabrutinib combined with PD-1 and fotemustine in the treatment of patients with primary central nervous system lymphoma (PCNSL).
- Trial name
- NCT04831658
- Testing
- the dose-escalation phase
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Mingzhi Zhang
Sarcoma
Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide
To determine the percentage of patients and number of cycles in which a packed red blood cell transfusion was administered due to anemia and in which antibiotics were administered due to neutropenic fever.
- Trial name
- NCT00283621
- Testing
- Aranesp (darbepoetin alfa), Neulasta (pegfilgrastim), Adriamycin
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Cancer NSCLC
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC…
- Trial name
- POSEIDON (NCT03164616)
- Testing
- Durvalumab, Tremelimumab, Abraxane + carboplatin
- Where
- 175 sites in United States, Brazil and 17 more
- Volunteers
- 1,186 people
- Sponsor
- AstraZeneca